The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study.
Inflammation
colorectal carcinoma
epidemiology
gastrointestinal cancer (GI cancer)
hepatocellular carcinoma
immunology
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
ppublish
Résumé
Lymphotoxin-beta receptor (LTβR) is an immunological protein associated with inflammation, and from preclinical studies is implicated in tumorigenesis. The epidemiological relationships with cancer are unknown, hence this study investigated their associations. From a multiethnic population-based cohort, 3,032 participants without a prevalent cancer (a diagnosis prior to or within one year of enrollment) at baseline underwent measurement of plasma LTβR. These participants were followed for incident cancer using the Texas Cancer Registry (TCR). Over a median follow-up of 12.1 years, 178 participants developed incident cancer, of which 30 participants developed incident gastrointestinal (GI) cancer. Median plasma LTβR (1.10 Increased plasma levels of LTβR are associated with the development of GI cancer. The antecedent findings years prior to a subsequent diagnosis of incident GI cancer suggest a role for LTβR in the pathogenesis of GI cancer. Further studies are needed to determine if LTβR can serve as an immune biomarker for GI cancer, in particular hepatocellular and colorectal cancers.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphotoxin-beta receptor (LTβR) is an immunological protein associated with inflammation, and from preclinical studies is implicated in tumorigenesis. The epidemiological relationships with cancer are unknown, hence this study investigated their associations.
METHODS
METHODS
From a multiethnic population-based cohort, 3,032 participants without a prevalent cancer (a diagnosis prior to or within one year of enrollment) at baseline underwent measurement of plasma LTβR. These participants were followed for incident cancer using the Texas Cancer Registry (TCR).
RESULTS
RESULTS
Over a median follow-up of 12.1 years, 178 participants developed incident cancer, of which 30 participants developed incident gastrointestinal (GI) cancer. Median plasma LTβR (1.10
CONCLUSIONS
CONCLUSIONS
Increased plasma levels of LTβR are associated with the development of GI cancer. The antecedent findings years prior to a subsequent diagnosis of incident GI cancer suggest a role for LTβR in the pathogenesis of GI cancer. Further studies are needed to determine if LTβR can serve as an immune biomarker for GI cancer, in particular hepatocellular and colorectal cancers.
Identifiants
pubmed: 32175103
doi: 10.21037/jgo.2020.01.04
pii: jgo-11-01-36
pmc: PMC7052776
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36-44Informations de copyright
2020 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Oncogene. 2010 Sep 9;29(36):5006-18
pubmed: 20603617
Clin Exp Immunol. 2004 Apr;136(1):21-9
pubmed: 15030510
Cancer Causes Control. 2013 Dec;24(12):2245-50
pubmed: 24052422
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393912
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Clin Cancer Res. 2017 Feb 1;23(3):623-629
pubmed: 27895032
Diabetes Care. 2005 Jun;28(6):1376-82
pubmed: 15920055
Am J Cardiol. 2004 Jun 15;93(12):1473-80
pubmed: 15194016
Gut. 2016 Oct;65(10):1765-75
pubmed: 26206664
Carcinogenesis. 2013 May;34(5):1105-14
pubmed: 23349015
Science. 1994 Apr 29;264(5159):707-10
pubmed: 8171323
Gastroenterology. 2011 Mar;140(3):799-808, quiz e11
pubmed: 21115010
J Exp Med. 2015 Feb 9;212(2):185-202
pubmed: 25601653
N Engl J Med. 2004 Dec 16;351(25):2599-610
pubmed: 15602020
J Immunol. 1995 Dec 1;155(11):5280-8
pubmed: 7594541
Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):301-10
pubmed: 22152226
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):545-550
pubmed: 29329668
Front Immunol. 2018 Nov 05;9:2546
pubmed: 30455695
Eur J Epidemiol. 2015 Mar;30(3):219-30
pubmed: 25446307
Lancet. 2002 Jun 22;359(9324):2159-63
pubmed: 12090982
J Immunol. 1995 Aug 15;155(4):1685-93
pubmed: 7636227
Atherosclerosis. 2010 Oct;212(2):601-6
pubmed: 20599198
J Biol Chem. 2008 May 23;283(21):14177-81
pubmed: 18385130
PLoS One. 2016 Sep 16;11(9):e0162845
pubmed: 27636369
Cell. 1993 Mar 26;72(6):847-56
pubmed: 7916655
Biochim Biophys Acta. 2016 Apr;1865(2):204-19
pubmed: 26923876
Curr Opin Immunol. 2013 Apr;25(2):222-9
pubmed: 23339845
Nat Genet. 2014 Jun;46(6):533-42
pubmed: 24836286
Cancer Cell. 2009 Oct 6;16(4):295-308
pubmed: 19800575
J Natl Cancer Inst. 2014 Apr;106(4):dju016
pubmed: 24565956
Immunity. 1998 Jul;9(1):59-70
pubmed: 9697836
Br J Cancer. 2013 May 14;108(9):1891-8
pubmed: 23591192
J Clin Med. 2019 Oct 23;8(11):
pubmed: 31652813
Apoptosis. 2004 Mar;9(2):123-30
pubmed: 15004509
J Thromb Haemost. 2011 Apr;9(4):638-44
pubmed: 21284802
J Natl Compr Canc Netw. 2015 Jul;13(7):873-8
pubmed: 26150581
Infect Immun. 2005 Nov;73(11):7077-88
pubmed: 16239501
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9697-702
pubmed: 18621708
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183